We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy.
reduction in plasma HDL cholesterol and apolipoprotein AI levels
rosiglitazone